donanemab Archives -

Roche starts new four-year trial of Alzheimer’s drug gantenerumab

Phil Taylor Alzheimer's disease, Biogen, donanemab, Eisai, Eli Lilly, gantenerumab, lecanemab, neurology, Roche 0 Comment

With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has

Roche starts new four-year trial of Alzheimer’s drug gantenerumab

https://pharmaphorum.com/news/roche-starts-new-four-year-trial-of-alzheimers-drug-gantenerumab/

Market Access/ News/ News

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, donanemab, Eli Lilly, Medicare, neurology, reimbursement 0 Comment

Eli Lilly has backed away from plans to file Alzheimer’s drug donanemab in the first quarter of this

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

https://pharmaphorum.com/news/lilly-defers-alzheimers-drug-filing-after-cms-disappointing-decision/

News/ News/ Sales and Marketing

Eli Lilly plans €400m Irish plant that will create 800 jobs

Phil Taylor Alzheimer's disease, biologics, donanemab, Eli Lilly, IDA Ireland, Ireland, manufacturing 0 Comment

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that

Eli Lilly plans €400m Irish plant that will create 800 jobs

https://pharmaphorum.com/news/eli-lilly-plans-e400m-irish-plant-that-will-create-800-jobs/

Market Access/ News/ News

Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trial

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, donanemab, Eisai, Eli Lilly, fda, neurology 0 Comment

Eli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab,

Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trial

https://pharmaphorum.com/news/lilly-files-alzheimers-drug-donanemab-as-cortexyme-rival-fails-trial/

News/ News/ R&D

With Alzheimer’s market opening up, Lilly forms neuroscience unit

Phil Taylor donanemab, Eli Lilly, immunology, neuroscience, R&D, senior management 0 Comment

Eli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the

With Alzheimer’s market opening up, Lilly forms neuroscience unit

https://pharmaphorum.com/news/lilly-forms-neuroscience-unit/

Market Access/ News/ News

Lilly sets out its stall on donanemab as filing approaches

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, donanemab, Eli Lilly, fda, neurology 0 Comment

The FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has emboldened Eli Lilly to move forward plans to

Lilly sets out its stall on donanemab as filing approaches

https://pharmaphorum.com/news/lilly-sets-out-its-stall-on-donanemab-as-filing-approaches/

News/ News/ R&D

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

Phil Taylor Alzheimer's disease, amyloid, antibody, Bristol-Myers Squibb, donanemab, Eli Lilly, neurology, Prothena, Tau 0 Comment

Just a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

https://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/

News/ News/ R&D

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

Phil Taylor aducanumab, Alzheimer's disease, amyloid, Biogen, donanemab, Eisai, Eli Lilly, neurology 0 Comment

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/

Trending

donanemab

Login